Breaking News, Collaborations & Alliances

Evotec SE and Sernova Corp Announce Partnership in the Field of Diabetes

Aim to develop an off-the-shelf iPSC-based beta cell replacement therapy device for the treatment of patients living with insulin-dependent diabetes.

Author Image

By: Charlie Sternberg

Associate Editor

Evotec SE and Sernova Corp., a clinical-stage company and leader in regenerative medicine cell therapeutics, have announced a partnership in the field of diabetes through which both companies will leverage their respective strengths to develop an implantable iPSC-based beta cell replacement therapy for the treatment of insulin-dependent diabetes, including type 1 and 2. The partnership leverages iPSC-based beta cells from Evotec’s QRbeta initiative. Evotec reliably produces human iPSC-based b...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters